Biacore Launches new Generation System for Protein Interaction Analysis

Unmatched performance of Biacore(R) T100 supports critical decision-making from research through to manufacturing and QC

Uppsala, SWEDEN


UPPSALA, Sweden, Feb. 7, 2005 (PRIMEZONE) -- Biacore International AB (Biacore) (SSE:BCOR) today announced the launch of Biacore(R) T100, a new generation system for protein interaction analysis.

Biacore(R) T100 provides comprehensive information about how proteins interact with other molecules. The unique information generated by Biacore(R) T100 is invaluable for many applications such as elucidation of disease pathways, definition of therapeutic targets, selection of drug candidates and decisions on the safety of a protein therapeutic.

Biacore(R) T100 sets the performance standard for protein interaction analysis, from research through drug discovery and development to manufacturing and QC, providing the highest quality data to support decisions that ensure productive research and development. From a single instrument, scientists can determine affinity and rate constants, binding specificity, concentration and thermodynamic parameters. In this way, applications as time-consuming as antibody characterization, which could take weeks by conventional methods, can be completed in days with Biacore(R) T100. Software wizards assist with the analysis of every interaction parameter, making the system straightforward to use and suitable for both novice and experienced users.

Initially acknowledged as essential in basic research, the unique data provided by Biacore systems are now widely used by biotechnology and pharmaceutical companies to make well-informed decisions at critical stages throughout the development and manufacture of novel therapeutics. To fulfill stringent regulatory requirements, Biacore T100 has been designed with a high level of in-built GLP/GMP/GCP support and 21 CFR Part 11 compliance. An optional GxP support package will save users significant time during validation.

Erik Wallden, Biacore's President and CEO commented:

"Biacore(R) T100 is our new flagship system, the fruit of our skills and expertise gained through 15 years of experience since we introduced real time protein interaction analysis into the life science market. We are confident that both existing and new Biacore users will benefit from the system's unmatched performance and ease-of-use. Biacore(R) T100 offers even greater opportunities for scientists to benefit from real time protein interaction analysis wherever they work in the life sciences."

About Biacore

Biacore is a global supplier of systems for protein interaction analysis, an area of increasing importance for scientists in the academic, pharmaceutical, biotechnology and diagnostic markets. The Company's systems generate unique data on the interactions between proteins and other molecules, including small molecules such as drug candidates. During research, development and manufacture, these data give insights into protein functionality, elucidate disease mechanisms and play a key role in the critical decisions needed for efficient development and production of therapeutics.

Biacore's products are used in key areas such as antibody characterization, proteomics, lead characterization, immunogenicity, biotherapeutic development and production. The Company offers a range of products to meet specific application needs. Customers include leading life science research centers, all of the leading global pharmaceutical companies, and a large number of companies in the emerging biotechnology sector.

Biacore also markets food analysis solutions, providing key manufacturers with a system and ready-to-use kits for the determination of food quality and safety.

The company has its own direct sales capability in the world's key markets (United States, Europe, Japan, Australia) and a distribution network in Asia-Pacific. Biacore was founded in 1984 and is listed on the Stockholm Stock Exchange (SSE:BCOR).

Further information on Biacore can be found at: www.biacore.com

Cautionary Statement

This press release contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, which, by their nature, involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Biacore is a trademark of Biacore AB.

For further information, please contact: Erik Wallden, President and CEO +41 (0) 79 769 4542

Scientific/Trade Press Enquiries:

Biacore:

Sue Cresswell, Market Communication Director +41 (0) 79 710 8311

Northbank Communications: Douglas Pretsell, Senior Account Manager +44 (0) 20 7886 8158

This information was brought to you by Waymaker http://www.waymaker.net

The following files are available for download:

http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=69676&fn=wkr0001.pdf